Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
PartnershipPositive
AI Analysis
Summary
Roche and Hansoh struck an ADC deal in which Roche picks cancer targets and Hansoh builds the conjugates, with $400 million upfront, a $110 million first-anniversary payment and over $15 billion in potential milestones. The structure mirrors AstraZeneca's January deal with CSPC.
Outcome Details
Roche selects cancer targets and Hansoh builds antibody-drug conjugates (ADCs); $400M upfront, $110M first-anniversary payment, and more than $15B in milestones.
Importance:8/10
Sentiment:
0.70
ADConcologylicensing dealpartnershipupfront paymentmilestonesChina biotech
Read the original article
Published by Drug Discovery & Development on October 19, 2026 11:46 PM